The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Statement from the Multiple Myeloma Research Foundation Regarding the Oncologic Drugs Advisory Committee (ODAC) Recommendation for Novartis’ Panobinostat for Multiple Myeloma

The Multiple Myeloma Research Foundation (MMRF) today issued the following statement regarding the Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) about the addition of panobinostat to a standard treatment combination for patients with multiple myeloma who have received at least one prior therapy. READ MORE

Posted: November 06, 2014

Multiple Myeloma Research Foundation Leads New Initiative to Accelerate Development of Targeted Therapies for Multiple Myeloma

The MM Master Protocol is a biomarker-driven, clinical trial that matches patients with relapsed disease with targeted therapies based on the genomic profile of their tumor. This approach builds on the work of MMRF’s Multiple Myeloma Genomics Initiative (MMGI), which established novel connections between the disease and important biomarkers and molecular targets. A key example of this is MMGI’s discovery, confirmed by other researchers, that the BRAF gene plays a role in a subset of myeloma cases. READ MORE

Posted: November 05, 2014

Multiple Myeloma Research Consortium (MMRC) Hits all Time Record-Opens Six New Clinical Trials in 2014

The Multiple Myeloma Research Consortium (MMRC) today announced that it has opened six new clinical trials in 2014, and is on track to open more multiple myeloma clinical trials during 2014 than any other year since the Consortium was founded in 2004. READ MORE

Posted: October 01, 2014

Page 86 of 87« First...102030...8384858687